| Literature DB >> 26912549 |
Antoine Bouquegneau1, Syrazah Salam2, Pierre Delanaye1, Richard Eastell3, Arif Khwaja4.
Abstract
Bone and mineral disorders occur frequently in kidney transplant recipients and are associated with a high risk of fracture, morbidity, and mortality. There is a broad spectrum of often overlapping bone diseases seen after transplantation, including osteoporosis as well as persisting high- or low-turnover bone disease. The pathophysiology underlying bone disorders after transplantation results from a complex interplay of factors, including preexisting renal osteodystrophy and bone loss related to a variety of causes, such as immunosuppression and alterations in the parathyroid hormone-vitamin D-fibroblast growth factor 23 axis as well as changes in mineral metabolism. Management is complex, because noninvasive tools, such as imaging and bone biomarkers, do not have sufficient sensitivity and specificity to detect these abnormalities in bone structure and function, whereas bone biopsy is not a widely available diagnostic tool. In this review, we focus on recent data that highlight improvements in our understanding of the prevalence, pathophysiology, and diagnostic and therapeutic strategies of mineral and bone disorders in kidney transplant recipients.Entities:
Keywords: Bone Diseases; Metabolic; Osteoporosis; Vitamin D; fibroblast growth factor 23; fracture; glucocorticoids; kidney transplantation; mineral metabolism; parathyroid hormone; renal osteodystrophy
Mesh:
Substances:
Year: 2016 PMID: 26912549 PMCID: PMC4934848 DOI: 10.2215/CJN.11371015
Source DB: PubMed Journal: Clin J Am Soc Nephrol ISSN: 1555-9041 Impact factor: 8.237